ACT-389949 is a potent and selective FPR2/ALX agonist, demonstrating an EC50 of 3 nM for receptor internalization in monocytes. This compound is a valuable research tool for investigating the resolution of inflammation and has shown potential in preclinical models of inflammatory diseases.